Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 42

Cited In for PubMed (Select 19736258)

1.

Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.

Gutfraind A, Galvani AP, Meyers LA.

JAMA Pediatr. 2015 Apr;169(4):341-8. doi: 10.1001/jamapediatrics.2014.3804.

PMID:
25706618
2.

Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States.

Pitzer VE, Viboud C, Alonso WJ, Wilcox T, Metcalf CJ, Steiner CA, Haynes AK, Grenfell BT.

PLoS Pathog. 2015 Jan 8;11(1):e1004591. doi: 10.1371/journal.ppat.1004591. eCollection 2015 Jan.

3.

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.

Homaira N, Rawlinson W, Snelling TL, Jaffe A.

Int J Pediatr. 2014;2014:571609. doi: 10.1155/2014/571609. Epub 2014 Dec 4. Review.

4.

Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants.

Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, Romagnoli C, Colonna P, Biondi A, Biban P, Chiamenti G, Bernardini R, Picca M, Cappa M, Magazzù G, Catassi C, Urbino AF, Memo L, Donzelli G, Minetti C, Paravati F, Di Mauro G, Festini F, Esposito S, Corsello G.

Ital J Pediatr. 2014 Oct 24;40:65. doi: 10.1186/1824-7288-40-65.

5.

Prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate.

Hsu CH, Lin CY, Chi H, Chang JH, Hung HY, Kao HA, Peng CC, Jim WT.

PLoS One. 2014 Oct 21;9(10):e110166. doi: 10.1371/journal.pone.0110166. eCollection 2014.

6.

[Evaluation of parental knowledge on acute bronchiolitis].

Gueddari W, Tazi A, Ouardi A, Nani S, Zineddine A.

Pan Afr Med J. 2014 Apr 24;17:310. doi: 10.11604/pamj.2014.17.310.2717. eCollection 2014. French. No abstract available.

7.

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation.

Robbie GJ, Makari D, Harris B, Losonsky GA, Jafri HS.

Infect Dis Ther. 2014 Sep 30. [Epub ahead of print]

8.

Burden of respiratory syncytial virus infection in young children.

Resch B.

World J Clin Pediatr. 2012 Oct 8;1(3):8-12. doi: 10.5409/wjcp.v1.i3.8. eCollection 2012 Oct 8.

10.

Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis.

Resch B.

Open Microbiol J. 2014 Jul 11;8:71-7. doi: 10.2174/1874285801408010071. eCollection 2014.

11.

Respiratory syncytial virus infections in infants affected by primary immunodeficiency.

Lanari M, Vandini S, Capretti MG, Lazzarotto T, Faldella G.

J Immunol Res. 2014;2014:850831. doi: 10.1155/2014/850831. Epub 2014 Jun 25. Review.

12.

A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.

Chi H, Hsu CH, Chang JH, Chiu NC, Hung HY, Kao HA, Weng LC, Huang FY, Chiu YY, Chang LY, Huang LM.

PLoS One. 2014 Jun 27;9(6):e100981. doi: 10.1371/journal.pone.0100981. eCollection 2014.

13.

Adherence to Immunoprophylaxis Regimens for Respiratory Syncytial Virus Infection in Insured and Medicaid Populations.

Escobar GJ, Gebretsadik T, Carroll K, Li SX, Walsh EM, Wu P, Mitchel E, Sloan C, Hartert T.

J Pediatric Infect Dis Soc. 2013 Sep;2(3):205-214. Epub 2013 Mar 21.

14.

RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction.

Liesman RM, Buchholz UJ, Luongo CL, Yang L, Proia AD, DeVincenzo JP, Collins PL, Pickles RJ.

J Clin Invest. 2014 May;124(5):2219-33. doi: 10.1172/JCI72948. Epub 2014 Apr 8.

15.

Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas.

Tapia LI, Shaw CA, Aideyan LO, Jewell AM, Dawson BC, Haq TR, Piedra PA.

PLoS One. 2014 Mar 13;9(3):e90786. doi: 10.1371/journal.pone.0090786. eCollection 2014.

16.

Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.

Ambrose CS, Anderson EJ, Simões EA, Wu X, Elhefni H, Park CL, Sifakis F, Groothuis JR.

Pediatr Infect Dis J. 2014 Jun;33(6):576-82. doi: 10.1097/INF.0000000000000219.

17.

Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Grunwald T, Tenbusch M, Schulte R, Raue K, Wolf H, Hannaman D, de Swart RL, Uberla K, Stahl-Hennig C.

J Virol. 2014 Apr;88(8):3997-4007. doi: 10.1128/JVI.02736-13. Epub 2014 Jan 22.

18.

Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.

Bawage SS, Tiwari PM, Pillai S, Dennis V, Singh SR.

Adv Virol. 2013;2013:595768. doi: 10.1155/2013/595768. Epub 2013 Dec 9. Review.

19.

Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease.

Kim YJ, Guthrie KA, Waghmare A, Walsh EE, Falsey AR, Kuypers J, Cent A, Englund JA, Boeckh M.

J Infect Dis. 2014 Apr 15;209(8):1195-204. doi: 10.1093/infdis/jit832. Epub 2013 Dec 23.

20.

Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.

Makari D, Checchia PA, Devincenzo J.

Hum Vaccin Immunother. 2014;10(3):607-14. Epub 2013 Dec 6. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk